Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cytotherapy

Showing results (571-580 of 3,134) with videos related to

Pageof 314
Sort By:
Cytotherapy|May 31, 2023
Suspension culture on microcarriers and as aggregates enables expansion and differentiation of pluripotent stem cells (PSCs)Haritha Vallabhaneni, Tanvi Shah, Parthiv Shah, et al.
Cytotherapy|May 22, 2026
AI-driven quality control of cell-based ATMPs: automated, accurate, and affordableRasmus Magnusson, Alice Hägg, Daniel Twohig, et al.
Cytotherapy|June 4, 2026
A pilot study of the CMV inSIGHT T-cell immunity panel to assess cytomegalovirus (CMV) cell mediated immunity (CMI) in allogeneic hematopoietic cell transplant (HCT) recipientsSwarn Arya, Rich Kodama, Yuxuan Li, et al.
Cytotherapy|June 4, 2026
Successful autologous T cell apheresis in pediatric patients with hematologic malignancies, solid tumors, and brain tumorsDevin Murphy, Yu Bi, Aysha Patel, et al.
Cytotherapy|April 3, 2026
Advancing acute myeloid leukemia immunotherapy: transcriptomic profiling-guided donor selection combined with an innovative natural killer cell expansion protocolEva Mašínová, Ioanna Papatheodorou, Veronika Švubová, et al.
Cytotherapy|March 31, 2026
Long-term stability of autologous peripheral blood stem cell products stored for up to 30 yearsPatrick Trépanier, Marie-Eve Rhéaume, Carl Simard, et al.
Cytotherapy|May 14, 2026
Impact of Blinatumomab and Inotuzumab Exposure on Apheresis Composition for CAR T in Patients With B-cell Acute Lymphoblastic LeukemiaAnna Cantilena, Kyu Lee Han, Yihua Cai, et al.
Cytotherapy|May 14, 2026
Chimeric antigen receptor-natural killer cell therapy in first-relapse epithelial ovarian cancer: an early health-economic evaluation in the NetherlandsAbril Seyahian, Mirre Scholte, Chantal Gravesteijn, et al.
Cytotherapy|March 14, 2026
Long-term follow-up of CD19 chimeric antigen receptor T cell therapy in acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantationShan Fu, Yinghui Yu, Mingming Zhang, et al.
Cytotherapy|February 28, 2026
Chronic graft-versus-host disease suppressing CD56<sup>bright</sup>Perforin<sup>neg</sup> regulatory-like NK cells inhibit CD4<sup>+</sup> T cells via PD-1, LAG-3, and TRAILMadeline P Lauener, Marie-Hélène Normand, Tracy Ngo, et al.
Pageof 314

Showing results (571-580 of 3,134) with videos related to

Sort By:
Pageof 314
Cytotherapy|May 31, 2023
Suspension culture on microcarriers and as aggregates enables expansion and differentiation of pluripotent stem cells (PSCs)Haritha Vallabhaneni, Tanvi Shah, Parthiv Shah, et al.
Cytotherapy|May 22, 2026
AI-driven quality control of cell-based ATMPs: automated, accurate, and affordableRasmus Magnusson, Alice Hägg, Daniel Twohig, et al.
Cytotherapy|June 4, 2026
A pilot study of the CMV inSIGHT T-cell immunity panel to assess cytomegalovirus (CMV) cell mediated immunity (CMI) in allogeneic hematopoietic cell transplant (HCT) recipientsSwarn Arya, Rich Kodama, Yuxuan Li, et al.
Cytotherapy|June 4, 2026
Successful autologous T cell apheresis in pediatric patients with hematologic malignancies, solid tumors, and brain tumorsDevin Murphy, Yu Bi, Aysha Patel, et al.
Cytotherapy|April 3, 2026
Advancing acute myeloid leukemia immunotherapy: transcriptomic profiling-guided donor selection combined with an innovative natural killer cell expansion protocolEva Mašínová, Ioanna Papatheodorou, Veronika Švubová, et al.
Cytotherapy|March 31, 2026
Long-term stability of autologous peripheral blood stem cell products stored for up to 30 yearsPatrick Trépanier, Marie-Eve Rhéaume, Carl Simard, et al.
Cytotherapy|May 14, 2026
Impact of Blinatumomab and Inotuzumab Exposure on Apheresis Composition for CAR T in Patients With B-cell Acute Lymphoblastic LeukemiaAnna Cantilena, Kyu Lee Han, Yihua Cai, et al.
Cytotherapy|May 14, 2026
Chimeric antigen receptor-natural killer cell therapy in first-relapse epithelial ovarian cancer: an early health-economic evaluation in the NetherlandsAbril Seyahian, Mirre Scholte, Chantal Gravesteijn, et al.
Cytotherapy|March 14, 2026
Long-term follow-up of CD19 chimeric antigen receptor T cell therapy in acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantationShan Fu, Yinghui Yu, Mingming Zhang, et al.
Cytotherapy|February 28, 2026
Chronic graft-versus-host disease suppressing CD56<sup>bright</sup>Perforin<sup>neg</sup> regulatory-like NK cells inhibit CD4<sup>+</sup> T cells via PD-1, LAG-3, and TRAILMadeline P Lauener, Marie-Hélène Normand, Tracy Ngo, et al.
Pageof 314